Schizophrenia is one of the most complex and serious psychiatric disorders. Despite decades of research, many of its causes remain unexplained. In recent years, interest in biomarkers has grown considerably, as they offer the possibility of putting diagnosis, prognosis and therapy on a more objective and personalized basis. Genetic, neurobiological, developmental and epigenetic factors play a central role here. This article summarizes the current state of research and shows perspectives on how biomarkers could revolutionize the clinical care of patients with schizophrenia in the future.
You May Also Like
- From symptom to diagnosis
Abdominal pain – Hernias
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- COPD therapy
Drug therapy – Update 2025
- Focus on prevention
Colorectal cancer screening – an update
- From symptom to diagnosis